Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abbott
Myriad and Abbott enter broad discovery collaboration to identify novel therapeutic targets
May 8th, 2006
Myriad Genetics, Inc. (MYGN) and Abbott (ABT) announced that the two companies have entered into a broad drug discovery collaboration to identify novel therapeutic targets. The collaboration will leverage proprietary technology platforms from both organizations to identify favorable targets amenable to drug discovery. Under the 5-year research agreement, Myriad will use its genetics, RNA expression profiling, and other discovery technologies, to identify human genes and regulatory networks associated with a variety of diseases. Myriad will evaluate differences in DNA and the RNA expression between thousands of individuals to identify the genetic...
Source: Biotech Week (2006-05-08)
|
